BioXcel Therapeutics (BTAI) Set to Announce Quarterly Earnings on Thursday

BioXcel Therapeutics (NASDAQ:BTAI) is scheduled to announce its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its earnings results on Tuesday, March 12th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.22. The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $1.17 million. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative return on equity of 890.63%. On average, analysts expect BioXcel Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioXcel Therapeutics Trading Up 0.8 %

NASDAQ BTAI opened at $2.54 on Thursday. The firm’s 50 day simple moving average is $2.84 and its 200 day simple moving average is $3.17. The firm has a market capitalization of $94.06 million, a price-to-earnings ratio of -0.41 and a beta of 0.40. BioXcel Therapeutics has a 1 year low of $1.91 and a 1 year high of $29.56.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BTAI. UBS Group reiterated a “neutral” rating and issued a $4.00 price target (down previously from $9.00) on shares of BioXcel Therapeutics in a research note on Wednesday, February 21st. Bank of America decreased their target price on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of BioXcel Therapeutics in a report on Tuesday, April 23rd. Finally, Canaccord Genuity Group dropped their price objective on shares of BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, March 14th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $16.71.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.